The FDA has accepted a New Drug Application (NDA) for Celcuity’s gedatolisib in hormone receptor positive (HR+), human ...
A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
Gedatolisib's NDA for advanced breast cancer treatment has been accepted by the FDA, with a priority review and a PDUFA date set for July 17, 2026. The drug is intended for HR+/HER2–, PIK3CA wild-type ...
News-Medical.Net on MSN
Atypical mutation offers clues to personalized pancreatic cancer treatment
A new study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026MINNEAPOLIS, (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: ...
TheFly reported on January 8 that Truist raised its price target on BBIO to $86 from $80 while maintaining a Buy rating.
A deep dive into the scientific shift toward multi-target obesity therapeutics and its implications for metabolic health and ...
Jones spoke to MHE after presenting research at the 2026 ASCO Gastrointestinal Cancers Symposium, held Jan. 8-10, in San ...
Roche expects filing for up to three new molecular entities in 2026, and accelerating its pipeline through partnerships and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback